Symbols / HOTH
HOTH Chart
About
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 16.29M |
| Enterprise Value | 7.84M | Income | -11.88M | Sales | — |
| Book/sh | 0.54 | Cash/sh | 0.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -1.48 | PEG | — |
| P/S | — | P/B | 1.93 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 7.76 |
| Current Ratio | 8.81 | Debt/Eq | 0.17 | LT Debt/Eq | — |
| EPS (ttm) | -1.02 | EPS next Y | -0.71 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 16:00 | ROA | -84.46% |
| ROE | -151.13% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 15.51M |
| Shs Float | 14.96M | Short Float | 5.07% | Short Ratio | 1.24 |
| Short Interest | — | 52W High | 2.12 | 52W Low | 0.66 |
| Beta | 0.54 | Avg Volume | 429.25K | Volume | 115.59K |
| Target Price | $5.00 | Recom | None | Prev Close | $1.01 |
| Price | $1.05 | Change | 3.96% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.00
Mean price target
2. Current target
$1.05
Latest analyst target
3. DCF / Fair value
$-7.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.05
Low
$5.00
High
$5.00
Mean
$5.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-04 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-11-17 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-07-30 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-07-23 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-06-26 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-06-12 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-04-15 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-04-03 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-03-31 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-03-10 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-03-06 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-03-04 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-02-11 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-01-23 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-01-07 | main | D. Boral Capital | Buy → Buy | $5 |
| 2024-11-04 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-07-26 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
- Cancer rash drug HT-001 draws so many patients Hoth adds Miami site - Stock Titan ue, 24 Feb 2026 21
- Hoth strikes back against cancer drug skin toxicities, but share price stays frozen - Fierce Biotech hu, 22 Jan 2026 08
- Hoth Therapeutics adds clinical site for skin toxicity trial - Investing.com ue, 24 Feb 2026 21
- Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth - PR Newswire Wed, 18 Jun 2025 07
- Hoth Therapeutics (HOTH) Price Target Increased by 11.11% to 5.10 - Nasdaq Wed, 04 Feb 2026 08
- Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Stocktwits ue, 10 Feb 2026 08
- 3 Under-the-Radar Biotechs Under $5 That Could Soar 200% - MarketBeat ue, 09 Sep 2025 07
- EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers - Yahoo Finance ue, 02 Sep 2025 07
- Hoth Therapeutics Files Two Provisional Patent Applications to Expand Product Portfolio - Pharmaceutical Executive Fri, 02 Jan 2026 08
- 2 Stocks to Buy Under $10 That Wall Street Loves - Barchart.com Wed, 29 Oct 2025 07
- Hoth Therapeutics (NASDAQ: HOTH) to Expand AI Drug R&D via NVIDIA Connect Program - Stock Titan hu, 20 Nov 2025 08
- Hoth Therapeutics (HOTH) Price Target Increased by 12.50% to 4.59 - Nasdaq Sat, 06 Dec 2025 08
- Hoth Therapeutics, Inc. (HOTH) Files EMA Application for Global Expansion of HT-001 Skin Therapy - Yahoo Finance ue, 23 Sep 2025 07
- Hoth Therapeutics stock rises after expanding AI initiative with NVIDIA - Investing.com Wed, 08 Oct 2025 07
- New patents target painful skin side effects from modern cancer treatments - Stock Titan Fri, 02 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 800000 | — | — | Stock Award(Grant) at price 0.00 per share. | KNIE ROBB | Chief Executive Officer | — | 2025-08-27 00:00:00 | D |
| 1 | 25000 | 16750 | — | Purchase at price 0.67 per share. | KNIE ROBB | Chief Executive Officer | — | 2024-08-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -8.24M | -7.80M | -10.68M | -13.95M |
| TotalUnusualItems | 27.71K | -157.55K | -386.91K | -152.68K |
| TotalUnusualItemsExcludingGoodwill | 27.71K | -157.55K | -386.91K | -152.68K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.19M | -8.11M | -11.37M | -14.31M |
| ReconciledDepreciation | 0.00 | |||
| EBITDA | -8.22M | -7.95M | -11.07M | -14.10M |
| EBIT | -8.22M | -7.95M | -11.07M | -14.10M |
| NetInterestIncome | 781.00 | 6.37K | 0.00 | |
| InterestIncome | 781.00 | 6.37K | 0.00 | |
| NormalizedIncome | -8.22M | -7.95M | -10.99M | -14.16M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.19M | -8.11M | -11.37M | -14.31M |
| TotalExpenses | 8.22M | 7.95M | 11.07M | 14.10M |
| RentExpenseSupplemental | 66.83K | 46.87K | ||
| TotalOperatingIncomeAsReported | -8.22M | -7.95M | -11.07M | -14.10M |
| DilutedAverageShares | 6.38M | 3.41M | 1.20M | 893.23K |
| BasicAverageShares | 6.38M | 3.41M | 1.20M | 893.23K |
| DilutedEPS | -1.28 | -2.38 | -9.50 | -16.02 |
| BasicEPS | -1.28 | -2.38 | -9.50 | -16.02 |
| DilutedNIAvailtoComStockholders | -8.19M | -8.11M | -11.37M | -14.31M |
| NetIncomeCommonStockholders | -8.19M | -8.11M | -11.37M | -14.31M |
| PreferredStockDividends | -990.00 | |||
| NetIncome | -8.19M | -8.11M | -11.37M | -14.31M |
| NetIncomeIncludingNoncontrollingInterests | -8.19M | -8.11M | -11.37M | -14.31M |
| NetIncomeContinuousOperations | -8.19M | -8.11M | -11.37M | -14.31M |
| PretaxIncome | -8.19M | -8.11M | -11.37M | -14.31M |
| OtherIncomeExpense | 27.13K | -153.15K | -312.77K | -212.26K |
| OtherNonOperatingIncomeExpenses | 451.14K | -59.58K | ||
| EarningsFromEquityInterest | -581.00 | 4.40K | -377.00K | 0.00 |
| GainOnSaleOfSecurity | 27.71K | -157.55K | -386.91K | -152.68K |
| NetNonOperatingInterestIncomeExpense | 781.00 | 6.37K | 0.00 | |
| InterestIncomeNonOperating | 781.00 | 6.37K | 0.00 | |
| OperatingIncome | -8.22M | -7.95M | -11.07M | -14.10M |
| OperatingExpense | 8.22M | 7.95M | 11.07M | 14.10M |
| ResearchAndDevelopment | 3.25M | 3.74M | 4.93M | 7.53M |
| SellingGeneralAndAdministration | 4.97M | 4.21M | 6.13M | 6.57M |
| GeneralAndAdministrativeExpense | 4.97M | 4.21M | 6.13M | 6.57M |
| OtherGandA | 4.97M | 4.21M | 6.13M | 3.49M |
| RentAndLandingFees | 66.83K | 46.87K | ||
| SalariesAndWages | 2.59M | 3.04M | ||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 8.04M | 4.35M | 1.30M | 958.98K |
| ShareIssued | 8.04M | 4.35M | 1.30M | 958.98K |
| TotalDebt | 31.07K | 55.16K | 0.00 | |
| TangibleBookValue | 6.88M | 9.54M | 5.12M | 9.88M |
| InvestedCapital | 6.88M | 9.54M | 5.12M | 9.88M |
| WorkingCapital | 6.81M | 9.47M | 5.34M | 9.71M |
| NetTangibleAssets | 6.88M | 9.54M | 5.12M | 9.88M |
| CapitalLeaseObligations | 31.07K | 55.16K | 0.00 | |
| CommonStockEquity | 6.88M | 9.54M | 5.12M | 9.88M |
| TotalCapitalization | 6.88M | 9.54M | 5.12M | 9.88M |
| TotalEquityGrossMinorityInterest | 6.88M | 9.54M | 5.12M | 9.88M |
| StockholdersEquity | 6.88M | 9.54M | 5.12M | 9.88M |
| GainsLossesNotAffectingRetainedEarnings | 9.06K | 27.26K | 22.01K | 17.59K |
| OtherEquityAdjustments | 9.06K | 27.26K | 22.01K | 17.59K |
| RetainedEarnings | -60.41M | -52.22M | -45.10M | -33.73M |
| AdditionalPaidInCapital | 67.28M | 61.73M | 50.20M | 43.59M |
| CapitalStock | 804.00 | 435.00 | 130.00 | 96.00 |
| CommonStock | 804.00 | 435.00 | 130.00 | 96.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 833.91K | 704.98K | 1.64M | 1.10M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.71K | 26.33K | 250.00K | 235.00K |
| NonCurrentAccruedExpenses | 0.00 | 250.00K | 235.00K | |
| LongTermDebtAndCapitalLeaseObligation | 2.71K | 26.33K | 0.00 | |
| LongTermCapitalLeaseObligation | 2.71K | 26.33K | 0.00 | |
| CurrentLiabilities | 831.20K | 678.66K | 1.39M | 867.79K |
| CurrentDebtAndCapitalLeaseObligation | 28.37K | 28.84K | ||
| CurrentCapitalLeaseObligation | 28.37K | 28.84K | 0.00 | |
| PayablesAndAccruedExpenses | 802.83K | 649.82K | 1.39M | 867.79K |
| CurrentAccruedExpenses | 390.76K | 614.23K | 692.74K | 506.82K |
| Payables | 412.07K | 35.59K | 694.99K | 360.96K |
| AccountsPayable | 412.07K | 35.59K | 694.99K | 360.96K |
| TotalAssets | 7.71M | 10.24M | 6.76M | 10.99M |
| TotalNonCurrentAssets | 67.89K | 92.56K | 33.00K | 410.00K |
| NonCurrentNoteReceivables | 0.00 | |||
| InvestmentsAndAdvances | 36.82K | 37.40K | 33.00K | 410.00K |
| LongTermEquityInvestment | 36.82K | 37.40K | 33.00K | 410.00K |
| InvestmentsinJointVenturesatCost | 36.82K | 37.40K | 33.00K | 410.00K |
| NetPPE | 31.07K | 55.16K | 0.00 | |
| AccumulatedDepreciation | 0.00 | -4.53K | ||
| GrossPPE | 31.07K | 59.70K | 0.00 | |
| OtherProperties | 55.16K | |||
| BuildingsAndImprovements | 31.07K | 59.70K | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 7.64M | 10.15M | 6.73M | 10.58M |
| PrepaidAssets | 559.18K | 811.36K | 88.45K | 93.97K |
| Receivables | 46.77K | 46.77K | 0.00 | 50.00K |
| OtherReceivables | 46.77K | 46.77K | ||
| NotesReceivable | 0.00 | 50.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 7.04M | 9.29M | 6.64M | 10.43M |
| OtherShortTermInvestments | 0.00 | 209.32K | 1.89M | |
| CashAndCashEquivalents | 7.04M | 9.29M | 6.43M | 8.54M |
| CashFinancial | 7.04M | 9.29M | 6.43M | 8.54M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.98M | -8.45M | -9.37M | -12.21M |
| RepurchaseOfCapitalStock | 0.00 | -10.00 | 0.00 | |
| IssuanceOfCapitalStock | 1.06M | 11.31M | 5.99M | 17.84M |
| CapitalExpenditure | -74.00K | -116.97K | ||
| EndCashPosition | 7.04M | 9.29M | 6.43M | 8.54M |
| BeginningCashPosition | 9.29M | 6.43M | 8.54M | 2.63M |
| EffectOfExchangeRateChanges | -18.20K | -6.52K | -9.59K | -30.56K |
| ChangesInCash | -2.24M | 2.87M | -2.10M | 5.94M |
| FinancingCashFlow | 4.74M | 11.32M | 6.04M | 18.19M |
| CashFlowFromContinuingFinancingActivities | 4.74M | 11.32M | 6.04M | 18.19M |
| NetOtherFinancingCharges | 50.00K | |||
| ProceedsFromStockOptionExercised | 3.68M | 2.35K | 0.00 | 359.51K |
| NetPreferredStockIssuance | 0.00 | 990.00 | 0.00 | |
| PreferredStockPayments | 0.00 | -10.00 | 0.00 | |
| PreferredStockIssuance | 0.00 | 1.00K | 0.00 | |
| NetCommonStockIssuance | 1.06M | 11.31M | 5.99M | 17.84M |
| CommonStockIssuance | 1.06M | 11.31M | 5.99M | 17.84M |
| InvestingCashFlow | 0.00 | 1.16M | -165.35K | |
| CashFlowFromContinuingInvestingActivities | 0.00 | 1.16M | -165.35K | |
| NetInvestmentPurchaseAndSale | 0.00 | 1.24M | -48.38K | |
| SaleOfInvestment | 0.00 | 1.24M | 2.51M | |
| PurchaseOfInvestment | 0.00 | -2.56M | ||
| NetBusinessPurchaseAndSale | 0.00 | |||
| PurchaseOfBusiness | 0.00 | |||
| NetIntangiblesPurchaseAndSale | 0.00 | -74.00K | -116.97K | |
| PurchaseOfIntangibles | 0.00 | -74.00K | -116.97K | |
| OperatingCashFlow | -6.98M | -8.45M | -9.30M | -12.09M |
| CashFlowFromContinuingOperatingActivities | -6.98M | -8.45M | -9.30M | -12.09M |
| ChangeInWorkingCapital | 405.19K | -487.32K | 594.48K | 529.92K |
| ChangeInPayablesAndAccruedExpense | 153.01K | -700.75K | 590.63K | 535.34K |
| ChangeInPayable | 535.34K | |||
| ChangeInAccountPayable | 535.34K | |||
| ChangeInPrepaidAssets | 252.18K | 213.43K | 3.85K | -5.42K |
| OtherNonCashItems | -275.00K | 34.00K | 92.47K | |
| StockBasedCompensation | 804.28K | 216.43K | 620.80K | 1.32M |
| UnrealizedGainLossOnInvestmentSecurities | 209.32K | -119.87K | 176.97K | |
| DepreciationAmortizationDepletion | 0.00 | |||
| DepreciationAndAmortization | 0.00 | |||
| Depreciation | 0.00 | |||
| OperatingGainsLosses | 581.00 | 204.92K | 944.69K | 101.39K |
| EarningsLossesFromEquityInvestments | -4.40K | 377.00K | 0.00 | |
| GainLossOnInvestmentSecurities | 209.32K | 567.69K | 41.81K | |
| NetForeignCurrencyExchangeGainLoss | 0.00 | 59.58K | ||
| GainLossOnSaleOfBusiness | 581.00 | -4.40K | 377.00K | 0.00 |
| NetIncomeFromContinuingOperations | -8.19M | -8.11M | -11.37M | -14.31M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for HOTH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|